Sermorelin (5mg)

Sermorelin is the first 29 residues of native human GHRH, with a C-terminal amide swapped in for the free acid. That amide change raises stability in vitro and leaves the receptor-binding region untouched.^[1] Guide to Pharmacology lists the sequence as Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln, matching the identity fields in the table above.

This listing is the free peptide, not the acetate salt used in the old Geref formulation, so molecular weight and formula will not match an acetate-salt COA. It is not full-length GHRH(1-44) either, and it is not somatropin, human growth hormone itself.

Sermorelin binds the growth-hormone-releasing hormone receptor, GHRHR, on pituitary somatotrophs. GHRHR is a G-protein-coupled receptor, and sermorelin mimics endogenous GHRH there to trigger growth hormone (GH) release.^[7] In healthy human subjects, both intravenous and intranasal dosing produced dose-dependent GH release. IV dosing hit peak GH within the first hour, and GH stayed elevated for roughly three hours after.^[2]

Endogenous GH secretion is pulsatile, not a flat line, so a single time-point GH sample is a source of variance on its own. The same study found no suppression of nocturnal GH pulsatility after repeated intranasal dosing. Assay design has to account for circadian rhythm and pulse-interval effects, or the numbers will not mean much.^[2]

The N-terminal Tyr-Ala bond in GHRH(1-29) is the main cleavage site for plasma dipeptidyl peptidase IV, DPP-IV. DPP-IV truncates the peptide to GHRH(3-29), which is largely inactive. A secondary trypsin-like cut at positions 12-13 accounts for a smaller share of total degradation.^[1] That is why unmodified GHRH(1-29) analogs run short plasma half-lives in kinetic studies.

Swap the position-2 L-Ala for D-Ala, as some longer-acting GHRH analogs do, and the DPP-IV step gets blocked. Controlled infusion studies showed a longer plasma half-life and a lower metabolic clearance rate than unmodified GHRH(1-29)-NH2.^[3] Running a pharmacokinetic or stability protocol? Write down protease inhibitors, processing speed, sampling times, and analog identity next to the batch Certificate of Analysis. Skip that step and degradation-rate comparisons turn into noise.

GHRH(1-29) and its metabolites can be picked up in plasma by immunoaffinity purification plus high-resolution LC-MS/MS, a method that tells intact peptide apart from GHRH(3-29).^[4] Use it to confirm integrity in a research sample. A purity percentage on a COA does not measure the same thing.

Sermorelin acetate was FDA-approved as Geref, for diagnosing and treating pediatric growth hormone deficiency. The manufacturer pulled it from the U.S. market in 2008. After a citizen petition, FDA published a March 2013 Federal Register notice stating that both Geref (sermorelin acetate) injection products were not withdrawn for safety or effectiveness reasons. That is a procedural finding, not a current marketing approval.^[6]

Geref trials mean the peptide carries clinical-trial-level human pharmacology data. Tetrava's sermorelin is still sold only as a research use only laboratory reagent: it is not dispensed, prescribed, or described as a medication, and this page makes no dosing, treatment, or anti-aging claims.

Labs often file sermorelin next to CJC-1295, ipamorelin, and tesamorelin, since all four touch the GH axis. They are not interchangeable controls, though.

• CJC-1295 is a modified GHRH(1-29) analog built, with or without a Drug Affinity Complex (DAC), for a longer plasma half-life. Same receptor class, longer action: not a different mechanism.
• Ipamorelin is a pentapeptide ghrelin-receptor (GHS-R1a) agonist, a different receptor from GHRHR entirely. Pairing the two probes a synergistic GH-secretagogue path, not an additive one.^[5]
• Tesamorelin is a stabilized GHRH(1-44) analog with a trans-3-hexenoic acid N-terminal modification, and the only GHRH analog with an active FDA-approved indication (HIV-associated lipodystrophy). Sermorelin's history is discontinued-but-not-unsafe, a different regulatory status entirely.^[5][6]
• Receptor, half-life, and regulatory status all differ. Swap one for another mid-protocol without re-checking dose-response and sampling intervals, and the comparative GH-axis data gets confounded.

People searching "sermorelin reddit" usually land on r/Peptides or r/Sermorelin. The threads cluster around subjective sleep or recovery reports, informal vendor purity or dosing comparisons, and stacking with other GH-axis peptides.

None of that is clinical evidence. Self-reported outcomes are unblinded and uncontrolled, and diet, training, and other compounds muddy the picture. Informal purity talk is not third-party HPLC-MS. Stacking anecdotes describe someone's personal practice, not a validated protocol. Treat the threads as a source of questions worth asking, like which COA a poster names or which analytical method a claim rests on, then go check the lot paperwork yourself.

Vendor quality is checkable before you buy sermorelin peptide from anyone. Before you treat a supplier as qualified, look at:

• Lot identity: does the listing give a batch/lot number that matches the Certificate of Analysis shipped with the vial, or is the PDF generic or old?
• COA/HPLC traceability: is the COA from an independent third-party lab, and does it report purity by area-under-curve HPLC rather than an in-house claim?
• Sequence and mass: does the COA (or an accompanying mass-spec report) confirm amino-acid sequence identity and molecular weight consistent with GHRH(1-29)-NH2? A purity percentage without those fields is incomplete.
• Storage and chain of custody: was the product shipped and stored in a way that matches a lyophilized peptide, with cold-chain notes where they apply?
• Support: can you get the underlying COA/HPLC report and reach someone who knows the lot, or is documentation withheld?
• If a vendor cannot produce a lot-specific COA on request for a currently listed batch, do not treat them as a qualified research supplier. Price and marketing copy do not fix that.

Searching "sermorelin peptide near me" will not get you far. This is a lab reagent sold online to qualified researchers and institutions, not something stocked on a pharmacy shelf or sold out of a local storefront.

Tetrava Labs ships sermorelin for sale from a single documented source, and an order placed across town gets the same lot paperwork as one placed across the country. A nearby address does not make a supplier more qualified. A matching, lot-specific COA does.

Tetrava Labs lists sermorelin in 5 mg and 10 mg vials, plus volume-tiered packs for labs running multi-vial protocols. The best place to buy sermorelin for a given protocol comes down to which strength and pack size fit your dosing math, not price alone. The current documented lot runs 99% purity by HPLC; cross-check the COA on your order against the COA library, since lot numbers rotate as new batches get qualified and older stock sells through.

Identity fields, CAS number, molecular formula, molecular weight, and sequence, for both strengths sit in the specifications table above. They come from the same lot records used to generate each batch COA, not from generic reference tables. Choose 5 mg versus 10 mg, and single-vial versus multi-vial, against that paperwork.

Tetrava Labs ships sermorelin as a lyophilized powder, which keeps it stable in transit. Store sealed vials at -20°C, and skip the freeze-thaw cycles. Reconstitute under sterile technique with a protocol-appropriate diluent right before use.

Sermorelin gets cleaved by DPP-IV in biological matrices.^[3] For stability or pharmacokinetic protocols, log diluent lot, reconstitution date, storage temperature, and sampling time points in the ELN. Keep those preparation records auditable against the batch Certificate of Analysis and the Growth Hormone Axis category's other GHRH- and GHRP-class reagents.